Traws Pharma (TRAW) FCF Margin (2012 - 2025)
Traws Pharma (TRAW) posted quarterly FCF Margin of 218.77% for Q2 2025, up 1706544.0% year-over-year from N/an in Q2 2024, and up 97.79% quarter-over-quarter from 9884.21% in Q1 2025.
Traws Pharma (TRAW) FCF Margin (2012 - 2025) Analysis & Trends
Traws Pharma (TRAW) has reported FCF Margin for 14 consecutive years, with 218.77% the latest figure, recorded in Q2 2025.
- In Q2 2025, FCF Margin rose 1706544.0% year-over-year to 218.77%; the TTM figure through Dec 2025 stood at 658.85% (up 1252345.0% YoY), while the FY2025 annual figure was 744.44%, up 1405202.0% from the prior year.
- FCF Margin climbed to 218.77% in Q2 2025 per TRAW's latest filing, from 9884.21% in the prior quarter.
- Across five years, FCF Margin topped out at 218.77% in Q2 2025 and bottomed at 20133.33% in Q3 2024.
- Historically, FCF Margin has averaged 8751.27% across 5 years, with a median of 7755.89% in 2022.
- Annual changes were most pronounced in 2024 — FCF Margin tumbled 1229298 bps — and 2025, when it soared 1706544 bps.
- Traws Pharma's FCF Margin stood at 7616.07% in 2021, then climbed by 9 bps to 6935.71% in 2022, then slipped by 14 bps to 7910.71% in 2023, then rose by 9 bps to 7214.29% in 2024, then soared by 97 bps to 218.77% in 2025.
- Business Quant data shows TRAW's FCF Margin at 218.77% in Q2 2025, 9884.21% in Q1 2025, and 7214.29% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Traws Pharma | 5.60 Mn | 588,417.40 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -218.77% |
| Mar 31, 2025 | -9,884.21% |
| Dec 31, 2024 | -7,214.29% |
| Sep 30, 2024 | -20,133.33% |
| Jun 30, 2024 | -17,284.21% |
| Mar 31, 2024 | -7,900.00% |
| Dec 31, 2023 | -7,910.71% |
| Sep 30, 2023 | -7,840.35% |
| Jun 30, 2023 | -7,877.19% |
| Mar 31, 2023 | -8,112.50% |
| Dec 31, 2022 | -6,935.71% |
| Sep 30, 2022 | -6,842.11% |
| Jun 30, 2022 | -7,392.98% |
| Mar 31, 2022 | -7,671.43% |
| Dec 31, 2021 | -7,616.07% |
| Sep 30, 2021 | -7,261.40% |
| Jun 30, 2021 | -7,556.14% |
| Mar 31, 2021 | -11,871.43% |
| Dec 31, 2020 | -9,592.98% |
| Sep 30, 2020 | -8,731.82% |